Myriad's FirstGene Validation Bolsters Prenatal Screening Play
Event summary
- Myriad Genetics published a study in Clinical Chemistry validating its FirstGene® Multiple Prenatal Screen, using nearly 500 samples.
- The study demonstrated ≥98.2% analytical sensitivity and ≥99.0% analytical specificity across all components of the test, including aneuploidy, recessive condition screening, and fetomaternal blood compatibility.
- FirstGene utilizes fetal-fraction amplification and a novel trajectory analysis algorithm to enhance genotype resolution.
- The test is currently being evaluated in the CONNECTOR study to assess real-world clinical performance and support clinical validity and utility.
The big picture
Myriad's FirstGene aims to consolidate multiple prenatal screening tests into a single assay, addressing a noted inefficiency in current US practices where less than half of pregnancies receive recommended screening for each modality. The high analytical sensitivity and specificity reported in this validation study are crucial for building clinician confidence and driving adoption, but the success of FirstGene hinges on demonstrating clinical utility and securing favorable reimbursement. The company's strategy of leveraging fetal-fraction amplification, similar to its Prequel test, suggests a broader platform approach to prenatal diagnostics.
What we're watching
- Clinical Adoption
- The CONNECTOR study's results will be critical; slow adoption could indicate underlying clinician hesitancy or competitive pressures impacting FirstGene's commercial prospects.
- Reimbursement
- Given the test's comprehensive nature and potential cost, securing favorable reimbursement rates will be essential for broad market access and profitability.
- Competitive Landscape
- The prenatal screening market is evolving rapidly; Myriad must demonstrate FirstGene’s sustained differentiation and value proposition against emerging competitors and alternative testing approaches.
Related topics